Santen Pharmaceutical Co Ltd
TSE:4536
Santen Pharmaceutical Co Ltd
TSE:4536
Price:
1 512.5 JPY
1.41%
Market Closed
Updated:
Apr 30, 2024
Santen Pharmaceutical Co Ltd
Net Income (Common)
|
Santen Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Comparables:
4502
4568
4578
4519
4503
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Santen Pharmaceutical Co Ltd
TSE:4536
|
Net Income (Common)
¥27.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
5%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Net Income (Common)
¥178.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
2%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Net Income (Common)
¥186.1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
23%
|
CAGR 10-Years
5%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Net Income (Common)
¥121.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-4%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Net Income (Common)
¥325.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
29%
|
CAGR 10-Years
20%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Net Income (Common)
¥37.3B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-9%
|
See Also
What is Santen Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
27.7B
JPY
27.7B
JPY
Based on the financial report for Dec 31, 2023, Santen Pharmaceutical Co Ltd's Net Income (Common) amounts to 27.7B JPY.
What is Santen Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
5%
5%
The average annual Net Income (Common) growth rates for Santen Pharmaceutical Co Ltd have been 4% over the past three years , -2% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
